Controlled dangerous substances; terms; pain management clinics; Oklahoma Bureau of Narcotics and Dangerous Drugs Control; exemptions; registration procedures; compliance; suspension; licensed prescriber; designated administrator; operations requirements; infection control; data collection; reporting; written policy; investigation by Bureau; penalties; rules; effective date.
HB2148 creates a new regulatory framework for pain management clinics in Oklahoma. It defines what qualifies as a pain management clinic, generally tying the definition to facilities that advertise pain management services and that prescribe opioids or certain other controlled substances to more than half of non-hospice/non-palliative patients for chronic nonmalignant pain. The bill requires most such clinics to register with the Oklahoma Bureau of Narcotics and Dangerous Drugs Control, with exemptions for certain academic, hospice/palliative, pain-free-prescribing, and mostly acute-pain practices.
The bill also imposes ownership and staffing rules. A clinic must be at least 51% physician-owned or owned by a licensed hospital, must designate an owner or administrator responsible for compliance, and must reapply if ownership changes. The Bureau is directed to deny or revoke registration in specified circumstances involving prescribers with revoked DEA numbers, denied controlled-substance authority, or certain felony drug convictions, though a rule-based exemption may be available after five years. If a registration is suspended or revoked, the clinic must stop operating as a pain management clinic, remove identifying signage, and affected persons are barred from reapplying for one year after revocation.
HB2148 also regulates how controlled substances may be prescribed in these clinics. Only an Oklahoma-licensed prescriber authorized to prescribe controlled dangerous substances may prescribe on the premises, dispensing is prohibited, and a physical exam must occur the same day a controlled substance is prescribed. Prescribers must safeguard prescription blanks and report theft or loss within 24 hours. The bill further requires clinics to maintain specific physical facilities, infection-control compliance, quality assurance programs, adverse-incident reporting, quarterly data reporting, and written procedures for transferring patients with substance use disorder. The Bureau and licensing boards are also authorized to investigate suspected drug diversion.
The bill’s impact on state law is to add a detailed licensing, inspection, reporting, and penalty regime for pain management clinics under Title 63. It gives the Bureau authority to fine clinics up to $1,000 per violation, assess daily penalties for ongoing violations or operating unregistered, and revoke or deny registration for misrepresentation or failure to register after a change in ownership. It also requires the Bureau and licensing boards to adopt rules to implement the new requirements, with an effective date of November 1, 2025.
Overall, the bill appears to have a strong public-safety and anti-diversion focus, and the available context shows no recorded committee debate or votes yet. The tone of the measure is regulatory and enforcement-oriented rather than controversial in the available record, but the most likely points of contention are the burden on pain clinics, the breadth of the definition of covered clinics, the ownership restrictions, and the reporting and compliance obligations imposed on prescribers and administrators.
HB2148 would amend Title 63 by adding new sections governing pain management clinics, including registration with the Oklahoma Bureau of Narcotics and Dangerous Drugs Control, ownership restrictions, operational standards, reporting duties, and enforcement penalties. It would affect pain clinics, licensed prescribers, clinic owners, administrators, and the Bureau, while also interacting with existing controlled dangerous substances and professional licensing statutes. The bill authorizes administrative fines, suspension or revocation of clinic registration, and rulemaking by the Bureau and appropriate licensing boards.
No committee transcript or vote record is provided, so there is no documented floor or committee sentiment to summarize. Based on the bill text, the measure reflects a generally supportive policy posture toward tighter oversight of pain management clinics and controlled-substance prescribing, with an emphasis on preventing diversion, improving patient safety, and ensuring accountability. The available context suggests the bill was introduced and referred without recorded opposition or endorsement in the materials provided.
The main potential points of contention are the scope of the definition of a pain management clinic, the requirement that clinics be majority physician-owned or hospital-owned, and the mandatory registration and reporting obligations. Clinics that advertise pain services or prescribe certain medications to a majority of patients for chronic nonmalignant pain could be swept into the regulatory scheme, which may be viewed as burdensome by providers. Prescribers and clinic operators may also object to the denial/revocation provisions tied to prior DEA or disciplinary history, the same-day exam requirement, the prohibition on dispensing on-site, and the fines for operating without registration or failing to reapply after ownership changes.